Skip to main content
Erschienen in: Journal of Cancer Education 4/2020

06.05.2019

Perception of Breast Cancer Risk in Over 11,000 Patients During Routine Mammography Exam

verfasst von: Baruch Abittan, Sarah Pachtman, Sarah Herman, Joseph Indelicato, Jonathan Herman

Erschienen in: Journal of Cancer Education | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

To assess women’s knowledge of personal breast cancer risk. Additionally, we aimed to determine how often physicians are discussing individualized risk assessments of breast cancer with their patients, and if those discussion affected risk perception. Surveys were distributed in radiology centers in New York and made available to patients presenting for routine mammography. As exact number of patients who viewed the survey is unknown, response rate could not be assessed. Data from the survey was used to calculate each patient’s personal breast cancer risk using the National Cancer Institute Breast Cancer Risk Assessment Tool. Each patient’s actual breast cancer risk was compared to her perceived risk. 15,006 subjects submitted the survey and 11,365 were included in the final analysis. Fourteen percent of women were accurate in their 5-year estimation as compared to calculated risk, and only 7% of respondents were accurate in their estimation of risk by 90 years of age. There was no association between time since discussion of breast cancer risk and accuracy of estimating personal breast cancer risk (p = 0.17). There was no difference in risk estimation accuracy between women who had ever or had never discussed risk with her physician (p = 0.1064). Patients’ perceived personal risk of developing breast cancer does not match the Gail model calculated risk. These findings hold true whether or not her physician had discussed personal breast cancer risk with her in the past. Further studies should determine effective strategies to educate patients about their breast cancer risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A (2001) Improving chronic illness care: translating evidence into action. Health Aff 20:64–78CrossRef Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A (2001) Improving chronic illness care: translating evidence into action. Health Aff 20:64–78CrossRef
2.
Zurück zum Zitat Redmond N, Baer H, Clark C et al (2010) Sources of health information related to preventive health behaviors in a national study. Am J Prev Med 38(6):620–627.e2CrossRef Redmond N, Baer H, Clark C et al (2010) Sources of health information related to preventive health behaviors in a national study. Am J Prev Med 38(6):620–627.e2CrossRef
3.
Zurück zum Zitat Kamali S, Ahmadian L, Khajouei R, Bahaadinbeigy K (2018) Health information needs of pregnant women: information sources, motives and barriers. Health Inf Libr J 35:24–37CrossRef Kamali S, Ahmadian L, Khajouei R, Bahaadinbeigy K (2018) Health information needs of pregnant women: information sources, motives and barriers. Health Inf Libr J 35:24–37CrossRef
4.
Zurück zum Zitat Cull A, Anderson E, Campbell S, Mackay J, Smyth E, Steel M (1999) The impact of genetic counseling about breast cancer risk on women’s risk perceptions and levels of distress. Br J Cancer 79(3/4):501–508CrossRef Cull A, Anderson E, Campbell S, Mackay J, Smyth E, Steel M (1999) The impact of genetic counseling about breast cancer risk on women’s risk perceptions and levels of distress. Br J Cancer 79(3/4):501–508CrossRef
6.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7–30 Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7–30
8.
Zurück zum Zitat Edwards AG, Naik G, Ahmed H et al (2013) Personalised risk communication for informed decision making about taking screening tests. Cochrane Database Syst Rev (2):CD001865 Edwards AG, Naik G, Ahmed H et al (2013) Personalised risk communication for informed decision making about taking screening tests. Cochrane Database Syst Rev (2):CD001865
9.
Zurück zum Zitat Nekhlyudov L, Braddock C (2009) An approach to enhance communication about screening mammography in primary care. J Women’s Health 18(9):1403–1412CrossRef Nekhlyudov L, Braddock C (2009) An approach to enhance communication about screening mammography in primary care. J Women’s Health 18(9):1403–1412CrossRef
10.
Zurück zum Zitat Islami F, Torre LA, Drope JM et al (2017) Global cancer in women: cancer control priorities. Cancer Epidemiol Biomark Prev 26(4):458–470CrossRef Islami F, Torre LA, Drope JM et al (2017) Global cancer in women: cancer control priorities. Cancer Epidemiol Biomark Prev 26(4):458–470CrossRef
11.
Zurück zum Zitat Roth MY, Elmore JG, Yi-Frazier JP et al (2011) Self-detection remains a key method of breast cancer detection for U.S. women. J Women's Health (Larchmt) 20(8):1135–1139CrossRef Roth MY, Elmore JG, Yi-Frazier JP et al (2011) Self-detection remains a key method of breast cancer detection for U.S. women. J Women's Health (Larchmt) 20(8):1135–1139CrossRef
12.
Zurück zum Zitat Katapodi MC, Dodd MJ, Lee KA, Facione NC (2009) Underestimation of breast cancer risk: influence on screening behavior. Oncol Nurs Forum 36(3):306–314CrossRef Katapodi MC, Dodd MJ, Lee KA, Facione NC (2009) Underestimation of breast cancer risk: influence on screening behavior. Oncol Nurs Forum 36(3):306–314CrossRef
13.
Zurück zum Zitat Guerra CE, Sherman M, Armstrong K (2009) Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med 22:272–279CrossRef Guerra CE, Sherman M, Armstrong K (2009) Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med 22:272–279CrossRef
14.
Zurück zum Zitat Rockhill B, Spiegelman D, Byrne C et al (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358–366CrossRef Rockhill B, Spiegelman D, Byrne C et al (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358–366CrossRef
15.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886CrossRef Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886CrossRef
16.
Zurück zum Zitat Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548CrossRef Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548CrossRef
17.
Zurück zum Zitat Oeffinger KC, Fontham ET, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314(15):1599–1614CrossRef Oeffinger KC, Fontham ET, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314(15):1599–1614CrossRef
18.
Zurück zum Zitat Siu AL on behalf of the U.S. Preventive Services Task Force (2016) Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 164(4):279–296CrossRef Siu AL on behalf of the U.S. Preventive Services Task Force (2016) Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 164(4):279–296CrossRef
19.
Zurück zum Zitat Saslow D, Boetes C, Burke W et al (2007) American Cancer Society breast Cancer advisory group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRef Saslow D, Boetes C, Burke W et al (2007) American Cancer Society breast Cancer advisory group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRef
20.
Zurück zum Zitat Berg AO. US Preventive Services Task Force (2003) Chemoprevention of breast cancer: recommendations and rationale. Am J Nurs 103:107–113 Berg AO. US Preventive Services Task Force (2003) Chemoprevention of breast cancer: recommendations and rationale. Am J Nurs 103:107–113
21.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388CrossRef Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388CrossRef
22.
Zurück zum Zitat Berg W, Blume J, Cormack J et al (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299:2151–2163CrossRef Berg W, Blume J, Cormack J et al (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299:2151–2163CrossRef
Metadaten
Titel
Perception of Breast Cancer Risk in Over 11,000 Patients During Routine Mammography Exam
verfasst von
Baruch Abittan
Sarah Pachtman
Sarah Herman
Joseph Indelicato
Jonathan Herman
Publikationsdatum
06.05.2019
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 4/2020
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-019-01530-5

Weitere Artikel der Ausgabe 4/2020

Journal of Cancer Education 4/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.